Macquarie Group
LAB icon

Macquarie Group’s Standard BioTools LAB Stock Holding History

Macquarie Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,608
Closed -$53 – 2020
2024
Q1 		$53 Buy
+19,608
New +$47.3K ﹤0.01% 1652
2022
Q2 		– Sell
-11,162
Closed -$40 – 2600
2022
Q1 		$40 Hold
11,162
– – ﹤0.01% 2218
2021
Q4 		$44K Hold
11,162
– – ﹤0.01% 2198
2021
Q3 		$74K Buy
11,162
+9,229
+477% +$60.7K ﹤0.01% 2081
2021
Q2 		$12K Hold
1,933
– – ﹤0.01% 2453
2021
Q1 		$9K Buy
+1,933
New +$10.6K ﹤0.01% 2402
2016
Q1 		– Sell
-92,360
Closed -$998K – 1562
2015
Q4 		$998K Buy
+92,360
New +$907K ﹤0.01% 1081

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Macquarie Group's LAB Position: Q2 2024 in Review

Macquarie Group sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 19,608 shares — an estimated $53 sold.

Macquarie Group first reported a position in LAB in Q4 2015 and held it in 7 quarters. The position peaked at $998K in Q4 2015. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

  • Macquarie Group reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 19,608 Standard BioTools shares in Q2 2024, an estimated $53.
  • Macquarie Group first reported a position in Standard BioTools in Q4 2015 and held it in 7 quarters.
  • Macquarie Group's Standard BioTools position peaked at $998K in Q4 2015.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.